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America's pharmaceutical research companies: 
Keeping the cost of health care down 
Pharmaceutical Manufacturers Association 
A response to the staff report of the U.S. Senate Special Com-
mittee on Aging. 
The staff of the U.S. Senate Special Committee on Aging 
issued a report on September 24, 1991 intended for informa-
tional purposes. "It does not represent either findings or rec-
ommendations formally adopted by the Committee," accord-
ing to the report. 
The report is critical of America's pharmaceutical research 
companies on 5 principal points: prices, profits, marketing, 
research and tax credits. 
The staff report is biased and replete with factual errors, 
erroneous interpretations and misstatements. Then, on the 
basis of flawed findings, the report presents misguided policy 
options. 
America's pharmaceutical industry leads the rest of the 
world in innovation; the new drugs that are developed by the 
industry improve the health and quality of life of patients here 
and around the world. These medicines save lives and money. 
They often cure or control deadly diseases, shorten hospital 
stays, reduce physician visits and obviate surgery in millions 
of cases. Prescription medicines help hold down health-care 
costs. And they are the best hope for containing health-care 
costs in the future. 
The following addresses the report's principal allegations. 
Prescription drug prices/profitability 
Costs of discovering and developing pharmaceuticals have 
risen sharply. 
Industry-funded research and development expendi-
tures have doubled every 5 years since 1970, reaching 
$9.2 billion in 1991 -more than the total invested in 
biomedical research by all the National Institutes of 
Health. 
Drug prices have not risen as fast as the industry's 
R&D expenditures. In 1990, for example, the rise in 
pharmaceutical research was . virtually double the rate 
of drug price increases across the industry. 
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Compared with all other U.S. industries, the pharma-
ceutical industry devotes a higher percentage of sales 
revenues to R&D- 16.5% in 1990 for all PMA mem-
ber companies. This is more than 4 times the average 
of all industries. 
The latest estimate- by economists at Tufts Universi-
ty- of the cost of developing a new drug is $231 mil-
lion, up sharply from earlier estimates. 
A recent study by Duke University economist Henry 
Grabowski found that only 3 of every 10 drugs intro-
duced by the pharmaceutical industry between 1970 
and 1979 subsequently recovered their R&D costs. 
The Grabowski study-also concluded that if prices had 
risen at only the general rate of inflation since 1980, 
the industry could not have recovered its costs for this 
portfolio of drugs and R&D expenditures would have 
been adversely affected. 
The 1980s have seen greatly shortened product life cycles for 
pharmaceuticals. 
In 1984, the life cycle of pharmaceutical products that 
had lost patent protection was shortened dramatically 
with the passage of the Drug Price Competition and 
Patent Term Restoration Act (Waxman-Hatch), which 
made possible quick approval of generic copies of 
brand-name products. Within 2 years of patent expira-
tion, the typical pharmaceutical product now loses half 
of its market. This has put significant pressure on 
prices. 
Foreign patent piracy raises costs. 
Countries such as India, Brazil and Thailand steal an 
estimated $4.8 billion in patented inventions from U.S. 
pharmaceutical companies each year, according to the 
U.S. Trade Representatives and the International Trade 
Commission. 
A different Consumer Price Index (CPD base year would lead 
to different conclusions. 
To demonstrate that pharmaceutical price increases are 
advancing faster than other medical expenditures, the 
report uses 1980 as a base year. If the report had gone 
back to the CPI's previous base year of 1967, it would 
show that drug prices lagged behind the all-items CPI 
until 1990 - and still trails the CPI's medical compo-
nent by 200 points. (See chart.) 
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Regardless of what the report implies, the average cost 
of a prescription drug in the U.S. in 1990 was $19.94. 
U.S. versus Canadian prices. 
Canadian prescription-drug prices vary from province 
to province, depending on many factors. Ontario, for 
example, will pay for only the cheapest generic drugs 
for its elderly and indigent residents. A similar 
approach for Medicaid was proposed by Senator Pryor 
last year and soundly rejected. 
Canada is the only Western industrialized nation that 
links the market exclusivity of a patented product to its 
price. Adopting such a patent-crippling system in the 
United States would have the same effect in this coun-
try as Canada's traditionally weak patent system has 
had in Canada. It would impair the U.S. pharmaceuti-
cal industry's innovativeness, making it far less com-
petitive with drug industries in other industrialized 
countries, such as the United States, Japan, Germany 
and Switzerland, where patent laws are strong. 
The staff report fails to mention that Canada is the 
major industrial country with the weakest condition for 
pharmaceutical innovations, having contributed the 
least number of new compounds in recent years to cure 
diseases. Those who advocate Canada's system of 
price controls and weak patent protection invite a rapid 
decline in American pharmaceutical innovation, with 
disastrous consequences for the health of our citizens. 
Pharmaceutical industry profitability 
Investments in high-risk ventures - such as new drug 
development, where fewer than 1 in 5,000 chemicals 
or biologicals tested actually is ever marketed -
appropriately require a rate of return considerably 
higher than could be obtained from placing the same 
money in an average company. 
Pharmaceutical industry marketing 
Marketing practices conform to AMA guidelines 
The staff report's examples of "abusive marketing and 
promotional practices" do not reflect today's market. 
Pharmaceutical promotional practices conform to 
guidelines adopted by the American Medical Associa-
tion's House of Delegates on December 4, 1990, 
which the PMA Board of Directors adopted 2 days 
later. Since the guidelines forbid the practices cited in 
the report, legislative remedies are unnecessary. 
Pharmaceutical industry research 
Drug industry breakthrough research 
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The report asserts that "few breakthrough drugs" have 
resulted from the drug industry pricing policies that 
have sustained research and development. This ignores 
dozens of "break-through" drugs in past decades. They 
include biotechnology breakthroughs such as human 
growth hormone for dwarfism, interferon alpha for 
AIDS-related Kaposi's sarcoma, erythropoietin for 
dialysis-associated anemia and granulocyte colony 
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stimulating factor for chemotherapy-induced neutrope-
nia (low white blood cell count). It flagrantly ignores 
the many breakthrough "conventional" drugs and vac-
cines for diseases such as river blindness, African 
sleeping sickness, malaria, severe combined immuno-
deficiency disease (the so-called "Bubble Boy" dis-
ease), AIDS-associated cytomegalovirus retinitis, 
AIDS-associated cryptococcal meningitis and systemic 
candida! infections, hepatitis B, haemophilus influenza 
type B, and neonatal respiratory distress syndrome. 
And the R&D pipeline is bursting with future break-
throughs. 
The report shows little appreciation of the value of the 
second or third products on the market in a therapeutic 
category. These products, though perhaps not break-
throughs, often offer major advances in treatment and 
reduction in side effects. Examples include newer 
cephalosporin antibiotics requiring less frequent 
administration and enabling home intravenous use; 
improved cancer chemotherapeutic agents which elim-
inate hospitalization, and newer medications effective 
in the treatment of schizophrenia and depression. 
There are better ways to lower cost 
of providing needed medicines 
Policy options which might actually help reduce the cost of 
prescription drugs are: 
Streamline the drug approval process. The average 
cost of getting a drug onto the U.S. market could be 
cut substantially if clinical testing and FDA review 
times were reduced to that experienced in major Euro-
pean countries such as the United Kingdom. 
• Reduce patent piracy. U.S. research-based pharmaceu-
tical companies lose about $5 billion a year to interna-
tional patent pirates, who copy their drugs without per-
(Continued on page 19) >-
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AXID® 
nizatidine capsules 
Brief Summary. CoosuH the patl!age Insert for 
complete prescrllllng l1formatloft. 
Indications and Usage: 1. ActMl duodenal ulcer-
tO< up to 8 wee1<s of treatment at a dosage of 300 mg 
h.~ Of 150 mg b.i.d. Most patients heat within 4 weeks. 
2. Maintenance/her.lpy-10< healed duodenal ulcer 
patients at a dosage of I 50 mg h.s. at bedtime. The 
consequences of therapy with Axid lor tonger than 1 
year are oot known. 
3. GaSlrOeSO{Jha(JlliJI reDIJX disease (GE!ID)-10< up 
to 12 wee1<s of treatment ot endoscopically diagnosed 
esophagitis, including erosive and ulcerati"' esophagitis, 
and associated hearttlum at a dosage of 150 mg b.i.d. 
COitraindlcatlon: Known llypefsensitivity to the drug. 
Because cross sensitivity in this class ol oompoonds has 
been obser\'ed, H,-receptor antagonists, including Axid, 
should not be administered to patients with a history 
of hypersensitivity to other H,-receptOf antagonists. 
PrecautloRs: General-1 . Symptomatic respoose to nizatidine therapy does nat preclude the presence 
of gastric malignancy. 
2. Dosage should be reduced in patients with moderate to severe renal insufficiency. 
3. In patients with llOIITlal mnal funcli<Jn and uncomplicated hepatic dysfunclioo. the diS!lOSitioo of 
nizatidine is simoar to that in llOIITlal subjocts. 
Llborafory Tests- False-positive tests iur urobilinogen with Muttistix • may occur during therapy. 
Drug Interactions- No interactions have been observed with theophylline, cfllofdiazepoxide. lorazepam. 
lidocaine, phenytoin, and wartarin. Axid does not inhlbrt the cytochrome P-450 enzyme system; therelofe. 
drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. In patients given 
very high doses (3,900 mg) of aspirin daily, increased serum salicylate levels were seen when nizatidine, 
150 mg b.i.d., was administered concurrently. 
Carcinogenesis. Mutagenesis. lmpairmenl ol Fertility-A 2-year oral carcinogenicity study in rats with 
doses as hig!l as 500 rnglkg/day (aboot 80 times the recommended daily thefapeutic dose) showed no evidence 
ol a carcinogenic elfecl. There was a dose-related increase in the density of enterochromaffin-like (ECl) cet~ 
in the gastric oxyntic mucosa In a 2-year study in mice, there was no evidence ol a carcinogenic effect in male 
mice. altllough hyperplastic nodules of the liver were increased ill the high-dose males as oompared with 
placebo. Female mice given the high dose of Axid (2,000 rng/kglday, about 330 times the human dose) showed 
marginally stltislically significant increases in hepatic carcinoma and hepatic nodular hyperptasja with no 
numetical increase seen in any of the other dose groups.The rate of hepatic carcinoma in the high-dose 
animals was within the historical control limits seen IOf the strain of mice used. The female mice were giverl 
a dose larger than the maximum tolerated dose, as indicated by excessive (30%) weight decrement as compared 
with concurrent contr~ and evidence of mild liver injury (transaminase alevations). The occurrence of a marginal 
finding at high dose only in animals given an excessive and somewhal hepatotoxic dose, with no evidence of a 
carcinogenic elfect in rats, male mice, and female mice (giverl up to 360 rng/kglday, about 60 times the human 
dose). and a negative mutagenicity battery am oot ronsidered evidence at a carcinogenic prrtentiaiiOf Axid. 
Axid was not mutagenic in a battery of tests performed to evaluate its potential genetic toxicity, including 
bacterial mutation tests, unscfleduled DNA synthesis, sister cflromatid excflange, mouse lymphoma assay. 
cflromosome aberration tests, and a mie<onuciOIJs test 
In a 2-generalioo, perinatal and postnatal fertility study in rats, doses of nizatidine up to 650 mgii<Q/day 
produced no adverse effects on the reproductive pe~onmance of parental animals Of their progeny. 
Pregnancy- Teratogenic Effects-Pregnancy Caregory C-Oral reproduclioo studies in rats at doses up 
to 300 times the human dose and in llutcfl Belted rabiJits at doses up to 55 times the human dose revealed no 
evidence of impaired fertility or teratogenic effect; but, at a dose equivalent to 300 times the human dose. 
treated rabbits had abortions, decreased number of live fetuses, and depressed fetal weights. On intravenous 
administration to pregnant New Zealand White rabbits, nizatidine at 20 mg/kg produced cardiac enlargement. 
coarctatioo of the aortic arcfl, and cutarreous edema in 1 fetus, and at 50 mglkg. ~ produced ventricular 
anomaly, distendOO abdomen, spina bifida. hydrocephaly. and enlarged heart in 1 fetus. Thet"e are. however, 
no adequate and weft-controlled studies in pregnant women. n is also not known wllether nllatidine can · 
cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nllatidine 
should be used during prngnancy only if the potential benefit justifies the potential risk to the fetus. 
Nutsing Mothets-Siudies in lactating women have shown that 0.1% of an oral dose is secreted 
in human milk in proportioo to plasma concentrations. Because of growth depression in pups reared 
by treated lactating rats, a decision should be made whether to d~ntinue nursing or the drug, taking 
into account the importance of the drug to the mother. 
Podiatric Use-Safety and effectiwness in cflildren have not been established. 
Use in Bderly Patients-Healing rates in elderty patients were ~milar to those in yoonger age groups 
as were the rates of ~ events and laboratory terrt abnormalities. Age alone may not be an important 
factor in the diS!lOSitioo of nizatidne. Elderly patients may have reduced renal function. 
Adverse Reactions: Worldwide, controlled dinical ma1s induded ""'r 6,000 patients given nizatidine in 
studies of varying durations. Placebo-controlled trials in the Unrted States and Canada induded over 2,600 patients 
given nizatidine and over t .700 given placebo. Among the adverse events in these ~trolled tri~ only 
anemia (0.2% liS 0%) and urticaria (0.5% liS 0.1%) were significantiy more common in the nizatidine groop. Of 
the adverse events that occurred at a ~equency of 1% or more, there was no stltislically significant difference 
between Axid and placebo in the incidence of any at these events (see package insert for complete information). 
A variety of less common events were also reported; rt was not possible to determine wllelher these 
were caused by nizatidine. 
1/epalic-Hepatoceflular injury (elevated liver enzyme tests Of alkaline pflosiJI!atlse) possibly Of probably 
related to nizatidine occurred in some patients. In some cases, there was marl<ed elevatioo (>500 lUll) in 
SGOT or SGPT and, in a single instance. SGPT was >2,000 lUlL The incidence of elevated liver ellZ)'r110S 
overall and elevations of up to 3 times the upper limrt of normal, however, did not significantly diftef from that 
in placebo patients. All abnO<malities were reversible after discontinuation of Axid. Since marl<et introduction, 
hepatitis and jaundice have been reported. Rare cases of cholestatic or mixed hepatocellular and cholestatic 
injury with jaundice have been reported with reversal of the abllOIITlalities after d~tinualioo of Axid. 
Cardiovascular -In dinical pharmacology studies, sOOrt episodes of asymptomatic ventricular tachycardia 
occurred in 2 individuals administered Axid and in 3 untreated subjocts. 
CNS-Rare cases of reversible mental confusion have been reported. 
Endocline-Ciinical pharmacology studies aAd controlled clinical trials sh!med no evidence of anti-
androgenic activity due to nizatidine. Impotence and decreased libido were reported with similar frequency 
by patients on nizatidlne and those oo placelxl. Gynecomastia has been reported rarely. 
Hematologic-Anemia was reported significanuy mO<e ~equenUy in nizatidine than in placeOO-treated 
patients. Fatal thrombocytopenia was reported in a patient treated with nizatidine and another H2-receptor 
antagonist This patient had previously experienced thrombocytopenia wllile taking othet" drugs. Rare cases 
of thrombocytopenic purpura have been reported. 
Integumental-Urticaria was reported significanUy more ~equeoUy in nizatidine- than in placebo-treated 
patients. Rash and exfoliative dermatitis were also reported. 
Hypersensitivity-As with other H2-recepl0f antagonists, rare cases of anaphyfam following nizatidine 
administration have been reported. Rare episodles of liypefsen~tlvity reactioos (eg, bronchospasm.laryngeal 
edema, rash. and eosiflOf)hilia) have been reported. 
Other-Hyperuricemia unassociated with gout or nephrofrthiasis was reported. Eosinophilia, fever, and 
nausea related to nizatidine have been reported. 
OverdGsage: Overdoses of Axid have been reported rarely. H overdosage occurs, activated cflarcoal. 
emesis, or lavage shoold be considered aloog with clinical monrtoring and supportive ther.!py. The ability of 
hemodialysis to remove nizatidine from the body has not been condusivefy demonstrated; however. due to its 
large volume of d~ibulioo, nizatidine is not expected to be efficiently removed from the body by this method. 
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mission. Intellectual property protection must be 
strengthened, not weakened as in Canada, and tough 
action taken against patent pirates. 
Cut product liability costs. The high cost of protecting 
against the possibility of high jury awards in product 
liability cases adds millions of dollars to drug costs. A 
refonn of the tort laws is needed, including protection 
against punitive damages for products that have been 
deemed safe and effective by the Food and Drug 
Administration. 
Conclusion 
The Senate Aging Committee's staff is singling out one 
competitive industry for price controls and weakened patent 
protection. If their recommendations are enacted, it would 
have a damaging effect on both health care and U.S. interna-
tional competitiveness. 
"ARE YOU SURE YOU'RE TAKING THAT 
VITAMIN PRESCRIPTION?" 
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